** Shares of medical device maker Abbott Laboratories ABT.N up 1.8% at $130.92
** ABT says its study of a continuous glucose monitoring (CGM) device called FreeStyle Libre showed a 78% reduction in the risk of hospitalization for heart-related issues in people with diabetes
** Co says the study of the device was conducted using data from the Swedish National Diabetes Register
** Co says significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors
** Libre technology is used for patients to see their real-time glucose numbers, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals
** Including session's moves, stock up 15.3% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.